Lakewood-Amedex Biotherapeutics
Develops topical Nu-3 gel for mildly infected diabetic foot ulcers.
Something off on this page? Send us feedback.
Profile
Develops topical Nu-3 gel for mildly infected diabetic foot ulcers, with other antimicrobial candidates in preclinical work for urinary and pulmonary infections. Operates as a pre-revenue, single-segment research program built around direct local delivery.
Develops antimicrobial therapies around Bisphosphocin compounds, which destabilize bacterial membranes in laboratory testing. The lead program, Nu-3, is a topical gel being prepared for a planned dose-response clinical study in mildly infected diabetic foot ulcers; earlier human work used a different solution formulation.
Explores related candidates for urinary tract infections through direct bladder instillation and for pulmonary infections through aerosol delivery. Manufacturing is outsourced, and a wound-care contract research organization will run the planned Nu-3 study.
Operates with no approved products, commercial revenue, sales force, marketing capability, or distribution infrastructure. Commercialization would require building, outsourcing, or partnering for these capabilities, while all manufacturing is outsourced.
Company facts
Key statistics
Analysts
No analyst consensus on record.
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Jun 30, 2026Cash & short-term investments $4.6M · Total debt $101.6K · Total assets $5.0M · Shareholders' equity $4.3M
- Revenue
- $0
- Operating income
- −$3.8M
- Net income
- −$3.8M
Dividends
No dividends on record.
Ownership
| Insiders4 holders · as of May 1, 2026 | 5.11% | 121.2K shares | |
| Otherremainder | 94.89% | 2.25M shares |
2.37M company shares as of Sep 1, 2026 · holders as of their latest filing
Two share counts disagree (2.37M in the company's Sep 1, 2026 report, 1.75M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Peter CeccacciInsiderofficer: Chief Financial Officer | 1.98% | 46,815 | Form 4filed May 1, 2026 ↗ |
Kelvin CooperInsiderdirector, officer: Chief Executive Officer | 1.27% | 30,059 | Form 4filed May 1, 2026 ↗ |
Thomas BalzerInsiderofficer: Chief Medical Officer | 1.08% | 25,532 | Form 4filed May 1, 2026 ↗ |
Leonard James DeRomaInsiderdirector | 0.79% | 18,774 | Form 4filed May 1, 2026 ↗ |
HPW Investments Holding Ltd.Strategic | —24.04% of class, as filed | — | 13Gfiled Jun 23, 2026 ↗ |
| See all 7 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
Peers
- Smith & Nephew (ADR)
Incumbent topical antimicrobial products in chronic diabetic foot wound care.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics | $2.97 | +18.33% | $4.4M | — | — | — | — |
| Smith & Nephew (ADR) | $29.20 | +1.48% | $12.08B | 19.0 | — | 1.9 | +3.7% |
| Median | 19.0 | — | 1.9 | +3.7% |